Mesothelioma is diagnosed through a combination of imaging scans, tissue biopsy, and specialized lab analysis, with the entire process often taking several weeks from the first abnormal finding to a confirmed diagnosis. Because mesothelioma mimics other conditions, including lung cancer and benign pleural disease, reaching a definitive answer requires multiple steps. A tissue sample examined under a microscope remains the only way to confirm the disease.
Why Mesothelioma Is Hard to Diagnose
The symptoms of pleural mesothelioma, the most common form, overlap heavily with other chest conditions. Shortness of breath, chest pain, and persistent cough can point to pneumonia, heart failure, or lung cancer just as easily. The disease also has an exceptionally long latency period after asbestos exposure, sometimes 20 to 50 years, so patients and doctors may not immediately connect current symptoms to a workplace exposure decades earlier.
Adding to the difficulty, mesothelioma cells can look remarkably similar to adenocarcinoma (a type of lung cancer) under a standard microscope. Distinguishing between the two requires specialized staining techniques on the tissue sample. Getting this distinction right matters enormously because the treatment approaches are different.
Imaging: The First Step
Most diagnostic paths begin with a chest X-ray, which reveals a unilateral pleural effusion (fluid buildup on one side of the chest) in 30% to 80% of patients at the time of their first visit. About half of patients show diffuse pleural thickening or lobular masses along the pleura on X-ray. These findings aren’t specific to mesothelioma, but they signal the need for more detailed imaging.
A CT scan is the primary tool for evaluating suspected mesothelioma. Pleural thickening appears on CT in 90% to 92% of patients, making it the single most common finding. Several CT features strongly suggest mesothelioma rather than benign disease: nodular or lobular thickening of the pleura, thickening greater than 1 centimeter, involvement of the tissue between the lung lobes (seen in 73% to 86% of cases), and thickening that wraps circumferentially around the lung. In advanced cases, the tumor forms a rind-like shell encasing the lung, which is visible as the affected side of the chest shrinks in volume.
Ultrasound plays a supporting role, particularly when doctors need to guide a needle into a pleural effusion or biopsy site. On ultrasound, mesothelioma appears as irregular, angular growths with unclear borders, sometimes forming a tapestry-like pattern with nodules. Using the same size thresholds as CT (pleural thickening over 1 cm), ultrasound can distinguish malignant from benign effusions with 79% sensitivity and 100% specificity.
PET scans and MRI are used selectively. PET scans help determine whether the disease has spread to lymph nodes or distant sites, while MRI is better at showing whether the tumor has invaded the chest wall or diaphragm muscle.
Biopsy: Confirming the Diagnosis
Imaging can raise strong suspicion, but only a tissue biopsy confirms mesothelioma. There are two main approaches, and the choice depends on the patient’s overall health and how accessible the tumor is.
CT-guided core needle biopsy is the less invasive option. A radiologist uses CT images to guide a needle through the chest wall into the thickened pleura, withdrawing small cylinders of tissue. Reported sensitivity ranges from 70% to 94%, with an overall diagnostic rate around 83%. The procedure is done under local anesthesia and typically takes under an hour.
Thoracoscopy (often called VATS, for video-assisted thoracoscopic surgery) offers a higher diagnostic yield of 90% to 95%. A surgeon inserts a small camera and instruments through one or two small incisions in the chest wall, allowing direct visualization of the pleural surface. This lets the surgeon take larger, more targeted biopsies from multiple sites. It also allows the surgeon to drain fluid and, if needed, perform a pleurodesis to prevent fluid from reaccumulating. Thoracoscopy can be done under local or general anesthesia.
In a head-to-head trial, CT-guided biopsy achieved an 87.5% diagnostic rate compared to 94.1% for thoracoscopy, a difference that was not statistically significant. For patients who are good surgical candidates, thoracoscopy is generally preferred because it provides more tissue and a direct look at the tumor’s extent. But CT-guided biopsy is a reasonable alternative for patients who can’t tolerate a surgical procedure.
How Pathologists Identify the Cell Type
Once tissue is obtained, a pathologist examines it under a microscope and performs immunohistochemistry (IHC), a staining process that uses antibodies to detect specific proteins on the cell surface. This step is critical because mesothelioma and lung adenocarcinoma can look nearly identical on routine staining.
Two markers are particularly reliable for mesothelioma. Calretinin and HBME-1 are positive in essentially all mesothelioma cases and negative in adenocarcinoma. Conversely, markers called TTF-1, CEA, and CK7 light up in lung adenocarcinoma but are absent in mesothelioma. Pathologists typically use a panel of both “positive” and “negative” markers to make the call with confidence. The differences between the two cancers on these stains are stark and statistically significant.
The pathologist also classifies the mesothelioma into one of three histological subtypes, which has major implications for prognosis and treatment options:
- Epithelioid: The most common subtype, found in up to 80% of cases. These tumors grow as sheets of rounded cells in multiple architectural patterns. Epithelioid mesothelioma generally responds better to treatment and carries the best prognosis of the three types.
- Sarcomatoid: Composed of spindle-shaped cells that grow in an infiltrative pattern. These tumors often show severe cellular abnormalities, including bizarre nuclei and atypical giant cells. Sarcomatoid mesothelioma is the most aggressive subtype and the hardest to treat.
- Biphasic: Contains a mix of both epithelioid and sarcomatoid cells, with each component making up at least 10% of the tumor. Prognosis depends heavily on the ratio: the more sarcomatoid tissue present, the worse the outlook.
Blood Tests and Biomarkers
There is currently no blood test that can diagnose mesothelioma on its own. The MESOMARK assay, which measures a protein called soluble mesothelin-related peptide (SMRP) in the blood, is the only FDA-authorized blood test related to mesothelioma. However, it is approved only as an aid for monitoring patients who already have a diagnosis, not for screening or initial detection. The FDA classified it as a “humanitarian use” device, meaning its effectiveness has not been formally demonstrated.
The test’s limitations are clear from its performance data. Among patients with confirmed mesothelioma, 48% had SMRP levels in the same range as healthy individuals. That means the test misses roughly half of all cases. It also produces elevated readings in some patients with heart disease, lung cancer, and other conditions. For these reasons, SMRP levels can be useful for tracking disease progression over time in a known mesothelioma patient, but they are not reliable enough to catch the disease in the first place.
Staging After Diagnosis
Once mesothelioma is confirmed, doctors determine how far it has spread using the TNM staging system. This classification looks at three factors: the extent of the primary tumor (T), whether nearby lymph nodes are involved (N), and whether the cancer has spread to distant sites (M).
In early stages (T1), the tumor is confined to the pleura on one side of the chest. At T2, it has grown into the tissue between the lung lobes, the diaphragm muscle, or the lung itself. T3 indicates invasion into the chest wall or the fat around the heart. T4 marks the most advanced local disease, with tumor growing into ribs, the spine, the heart muscle, or crossing to the opposite side of the chest.
Lymph node involvement is divided into two categories. N1 means cancer has reached lymph nodes on the same side of the chest. N2 means it has spread to lymph nodes on the opposite side or above the collarbone. Any spread to distant organs, such as the liver, bones, or brain, is classified as M1.
Staging combines information from CT, PET scans, and sometimes surgical exploration. It directly determines which treatment options are available. Patients with early-stage disease (roughly T1 or T2, N0, M0) may be candidates for surgery, while advanced-stage disease is typically managed with chemotherapy, immunotherapy, or a combination of both.
What the Process Looks Like in Practice
For most patients, the diagnostic journey begins with a visit to a primary care doctor for persistent breathlessness or chest discomfort. A chest X-ray reveals fluid or pleural thickening, prompting a CT scan. If the CT findings are suspicious, a biopsy is scheduled. The tissue goes to pathology, where IHC staining confirms or rules out mesothelioma and identifies the subtype. Staging scans follow to map the disease’s extent.
From the first suspicious imaging finding to a final pathology report, the process typically takes two to six weeks, depending on how quickly biopsies can be scheduled and how straightforward the pathology is. In some cases, particularly with sarcomatoid tumors or small biopsy samples, pathologists may request additional tissue or a second opinion, which can extend the timeline. Getting referred to a center with mesothelioma experience can reduce delays, since pathologists at high-volume centers see these tumors more frequently and are more comfortable making the call.